Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 320495, 7 pages
http://dx.doi.org/10.1155/2012/320495
Review Article

The CD39-Adenosinergic Axis in the Pathogenesis of Immune and Nonimmune Diabetes

1Immunology Research Centre, St. Vincent's Hospital Melbourne, Fitzroy 3065, Australia
2Department of Medicine, University of Melbourne, Parkville 3010, Australia

Received 18 May 2012; Accepted 27 July 2012

Academic Editor: John Stagg

Copyright © 2012 Joanne S. J. Chia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. C. Robson, J. Sévigny, and H. Zimmermann, “The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance,” Purinergic Signalling, vol. 2, no. 2, pp. 409–430, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Kukulski, S. A. Levesque, E. G. Lavoie et al., “Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8,” Purinergic Signal, vol. 1, no. 2, pp. 193–204, 2005. View at Google Scholar
  3. S. Deaglio, K. M. Dwyer, W. Gao et al., “Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression,” Journal of Experimental Medicine, vol. 204, no. 6, pp. 1257–1265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. H. K. Eltzschig, D. Kö hler, T. Eckle, T. Kong, S. C. Robson, and S. P. Colgan, “Central role of Sp1-regulated CD39 in hypoxia/ischemia protection,” Blood, vol. 113, no. 1, pp. 224–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Synnestvedt, G. T. Furuta, K. M. Comerford et al., “Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia,” Journal of Clinical Investigation, vol. 110, no. 7, pp. 993–1002, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. S. P. Colgan, H. K. Eltzschig, T. Eckle, and L. F. Thompson, “Physiological roles for ecto-5'-nucleotidase (CD73),” Purinergic Signalling, vol. 2, no. 2, pp. 351–360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Bavaresco, A. Bernardi, E. Braganhol, M. R. Wink, and A. M. O. Battastini, “Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line,” Journal of Neuro-Oncology, vol. 84, no. 1, pp. 1–8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Node, M. Kitakaze, T. Minamino et al., “Activation of ecto-5'-nucleotidase by protein kinase C and its role in ischaemic tolerance in the canine heart,” British Journal of Pharmacology, vol. 120, no. 2, pp. 273–281, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. K. A. Jacobson, “Introduction to adenosine receptors as therapeutic targets,” Handbook of Experimental Pharmacology, vol. 193, pp. 1–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Zheng, R. Wang, E. Zambraski, D. Wu, K. A. Jacobson, and B. T. Liang, “Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury,” American Journal of Physiology, vol. 293, no. 6, pp. H3685–H3691, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. B. Newgard and J. Denis McGarry, “Metabolic coupling factors in pancreatic β-cell signal transduction,” Annual Review of Biochemistry, vol. 64, pp. 689–719, 1995. View at Google Scholar · View at Scopus
  12. C. Richards-Williams, J. L. Contreras, K. H. Berecek, and E. M. Schwiebert, “Extracellular ATP and zinc are co-secreted with insulin and activate multiple P2X purinergic receptor channels expressed by islet beta-cells to potentiate insulin secretion,” Purinergic Signalling, vol. 4, no. 4, pp. 393–405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. C. Jacques-Silva, M. Correa-Medina, O. Cabrera et al., “ATP-gated P2X3 receptors constitute a positive autocrine signal for insulin release in the human pancreatic β cell,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 14, pp. 6465–6470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Léon, M. Freund, O. Latchoumanin et al., “The P2Y1 receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice,” Purinergic Signalling, vol. 1, no. 2, pp. 145–151, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ohtani, J. I. Suzuki, K. A. Jacobson, and T. Oka, “Evidence for the possible involvement of the P2Y6 receptor in Ca2+ mobilization and insulin secretion in mouse pancreatic islets,” Purinergic Signalling, vol. 4, no. 4, pp. 365–375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. E. G. Lavoie, M. Fausther, G. Kauffenstein et al., “Identification of the ectonucleotidases expressed in mouse, rat, and human Langerhans islets: potential role of NTPDase3 in insulin secretion,” American Journal of Physiology, vol. 299, no. 4, pp. E647–E656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. B. M. Künzli, P. O. Berberat, T. Giese et al., “Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease,” American Journal of Physiology, vol. 292, no. 1, pp. G223–G230, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Novak, “Purinergic receptors in the endocrine and exocrine pancreas,” Purinergic Signalling, vol. 4, no. 3, pp. 237–253, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. R. C. McEvoy, J. Andersson, S. Sandler, and C. Hellerstrom, “Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line,” Journal of Clinical Investigation, vol. 74, no. 3, pp. 715–722, 1984. View at Google Scholar · View at Scopus
  20. M. Lin, N. Yin, B. Murphy et al., “Immune cell-derived C3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin,” Diabetes, vol. 59, no. 9, pp. 2247–2252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Nakamura, S. Nagafuchi, K. Yamaguchi, and R. Takaki, “The role of thymic immunity and insulitis in the development of streptozocin-induced diabetes in mice,” Diabetes, vol. 33, no. 9, pp. 894–900, 1984. View at Google Scholar · View at Scopus
  22. E. A. Green, Y. Choi, and R. A. Flavell, “Pancreatic lymph node-derived CD4+CD25+ treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals,” Immunity, vol. 16, no. 2, pp. 183–191, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Kukreja, G. Cost, J. Marker et al., “Multiple immuno-regulatory defects in type-1 diabetes,” Journal of Clinical Investigation, vol. 109, no. 1, pp. 131–140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Borsellino, M. Kleinewietfeld, D. Di Mitri et al., “Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression,” Blood, vol. 110, no. 4, pp. 1225–1232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. K. M. Dwyer, S. Deaglio, S. Crikis et al., “Salutary roles of CD39 in transplantation,” Transplantation Reviews, vol. 21, no. 1, pp. 54–63, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. K. M. Dwyer, D. Hanidziar, P. Putheti et al., “Expression of CD39 by human peripheral blood CD4+CD25+ T cells denotes a regulatory memory phenotype,” American Journal of Transplantation, vol. 10, no. 11, pp. 2410–2420, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. K. M. Dwyer, S. Deaglio, W. Gao, D. Friedman, T. B. Strom, and S. C. Robson, “CD39 and control of cellular immune responses,” Purinergic Signalling, vol. 3, no. 1-2, pp. 171–180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Enjyoji, K. Kotani, C. Thukral et al., “Deletion of Cd39/Entpd1 results in hepatic insulin resistance,” Diabetes, vol. 57, no. 9, pp. 2311–2320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. K. M. Dwyer, S. C. Robson, H. H. Nandurkar et al., “Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation,” Journal of Clinical Investigation, vol. 113, no. 10, pp. 1440–1446, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. K. M. Dwyer, T. B. Mysore, S. Crikis et al., “The transgenic expression of human CD39 on murine islets inhibits clotting of human blood,” Transplantation, vol. 82, no. 3, pp. 428–432, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. O. Andersson, B. A. Adams, D. Yoo et al., “Adenosine signaling promotes regeneration of pancreatic beta cells in vivo,” Cell Metabolism, vol. 15, no. 6, pp. 885–894, 2012. View at Google Scholar
  32. J. P. Annes, J. H. Ryu, K. Lam et al., “Adenosine kinase inhibition selectively promotes rodent and porcine islet beta-cell replication,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 10, pp. 3915–3920, 2012. View at Google Scholar
  33. J. J. Kobie, P. R. Shah, L. Yang, J. A. Rebhahn, D. J. Fowell, and T. R. Mosmann, “T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine,” Journal of Immunology, vol. 177, no. 10, pp. 6780–6786, 2006. View at Google Scholar · View at Scopus
  34. L. F. Thompson, H. K. Eltzschig, J. C. Ibla et al., “Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia,” Journal of Experimental Medicine, vol. 200, no. 11, pp. 1395–1405, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Zernecke, K. Bidzhekov, B. Özüyaman et al., “CD73/Ecto-5'-nucleotidase protects against vascular inflammation and neointima formation,” Circulation, vol. 113, no. 17, pp. 2120–2127, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Eckle, M. Faigle, A. Grenz, S. Laucher, L. F. Thompson, and H. K. Eltzschig, “A2B adenosine receptor dampens hypoxia-induced vascular leak,” Blood, vol. 111, no. 4, pp. 2024–2035, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. H. K. Eltzschig, L. F. Thompson, J. Karhausen et al., “Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism,” Blood, vol. 104, no. 13, pp. 3986–3992, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Takedachi, D. Qu, Y. Ebisuno et al., “CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes,” Journal of Immunology, vol. 180, no. 9, pp. 6288–6296, 2008. View at Google Scholar · View at Scopus
  39. B. Lu, S. V. Rajakumar, S. C. Robson et al., “The impact of purinergic signaling on renal ischemia-reperfusion injury,” Transplantation, vol. 86, no. 12, pp. 1707–1712, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Rajakumar and K. Dwyer, “Ischaemia reperfusion injury in kidney transplantation,” in Organ Donation and Transplantation—Public Policy and Clinical Perspectives, G. Randhawa, Ed., pp. 173–190, InTech, Vienna, Austria, 2012. View at Google Scholar
  41. S. V. Rajakumar, B. Lu, S. Crikis et al., “Deficiency or inhibition of CD73 protects in mild kidney ischemia-reperfusion injury,” Transplantation, vol. 90, no. 12, pp. 1260–1264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. G. I. L. Lunkes, D. S. Lunkes, V. M. Morsch et al., “NTPDase and 5'-nucleotidase activities in rats with alloxan-induced diabetes,” Diabetes Research and Clinical Practice, vol. 65, no. 1, pp. 1–6, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. Z. H. Németh, D. Bleich, B. Csóka et al., “Adenosine receptor activation ameliorates type 1 diabetes,” The FASEB Journal, vol. 21, no. 10, pp. 2379–2388, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Tudurí, E. Filiputti, E. M. Carneiro, and I. Quesada, “Inhibition of Ca2+ signaling and glucagon secretion in mouse pancreatic α-cells by extracellular ATP and purinergic receptors,” American Journal of Physiology, vol. 294, no. 5, pp. E952–E960, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. G. K. Yang, P. E. Squires, F. Tian, T. J. Kieffer, Y. N. Kwok, and N. Dale, “Glucose decreases extracellular adenosine levels in isolated mouse and rat pancreatic islets,” Islets, vol. 4, no. 1, pp. 64–70, 2012. View at Google Scholar
  46. J. Chapal, M. M. Loubatieres-Mariani, P. Petit, and M. Roye, “Evidence for an A2-subtype adenosine receptor on pancreatic glucagon secreting cells,” British Journal of Pharmacology, vol. 86, no. 3, pp. 565–569, 1985. View at Google Scholar · View at Scopus
  47. E. J. Verspohl, B. Johannwille, A. Waheed, and H. Neye, “Effect of purinergic agonists and antagonists on insulin secretion from INS-1 cells (insulinoma cell line) and rat pancreatic islets,” Canadian Journal of Physiology and Pharmacology, vol. 80, no. 6, pp. 562–568, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Rüsing, C. E. Müller, and E. J. Verspohl, “The impact of adenosine and A2B receptors on glucose homoeostasis,” Journal of Pharmacy and Pharmacology, vol. 58, no. 12, pp. 1639–1645, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. J. Day, L. Huang, H. Ye, L. Li, J. Linden, and M. D. Okusa, “Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-γ,” Journal of Immunology, vol. 176, no. 5, pp. 3108–3114, 2006. View at Google Scholar · View at Scopus
  50. Y. J. Day, L. Huang, H. Ye, J. Linden, and M. D. Okusa, “Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages,” American Journal of Physiology, vol. 288, no. 4, pp. F722–F731, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Grenz, H. Zhang, M. Hermes et al., “Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury,” The FASEB Journal, vol. 21, no. 11, pp. 2863–2873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. H. García-Hernández, L. Portales-Cervantes, N. Cortez-Espinosa et al., “Expression and function of P2X7 receptor and CD39/Entpd1 in patients with type 2 diabetes and their association with biochemical parameters,” Cellular Immunology, vol. 269, no. 2, pp. 135–143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. G. I. Lunkes, D. Lunkes, F. Stefanello et al., “Enzymes that hydrolyze adenine nucleotides in diabetes and associated pathologies,” Thrombosis Research, vol. 109, no. 4, pp. 189–194, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. D. J. Friedman, H. G. Rennke, E. Csizmadia, K. Enjyoji, and S. C. Robson, “The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephropathy,” Diabetes, vol. 56, no. 9, pp. 2371–2379, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. D. J. Friedman, M. E. Talbert, D. W. Bowden et al., “Functional ENTPD1 polymorphisms in african americans with diabetes and end-stage rnal disease,” Diabetes, vol. 58, no. 4, pp. 999–1006, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. S. M. Johansson, A. Salehi, M. E. Sandström et al., “A1 receptor deficiency causes increased insulin and glucagon secretion in mice,” Biochemical Pharmacology, vol. 74, no. 11, pp. 1628–1635, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Budohoski, R. A. J. Challiss, and G. J. Cooney, “Reversal of dietary-induced insulin resistance in muscle of the rat by adenosine deaminase and an adenosine-receptor antagonist,” Biochemical Journal, vol. 224, no. 1, pp. 327–330, 1984. View at Google Scholar · View at Scopus
  58. R. A. J. Challis, L. Budohoski, B. McManus, and E. A. Newsholme, “Effects of an adenosine-receptor antagonist on insulin-resistance in soleus muscle from obese Zucker rats,” Biochemical Journal, vol. 221, no. 3, pp. 915–917, 1984. View at Google Scholar · View at Scopus
  59. R. A. Figler, G. Wang, S. Srinivasan et al., “Links between Insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans,” Diabetes, vol. 60, no. 2, pp. 669–679, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. V. Large and P. Arner, “Regulation of lipolysis in humans. Pathophysiological modulation in obesity diabetes, and hyperlipidaemia,” Diabetes and Metabolism, vol. 24, no. 5, pp. 409–418, 1998. View at Google Scholar · View at Scopus
  61. Q. Dong, H. N. Ginsberg, and B. F. Erlanger, “Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity-related insulin resistance,” Diabetes, Obesity and Metabolism, vol. 3, no. 5, pp. 360–366, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Faulhaber-Walter, W. Jou, D. Mizel et al., “Impaired glucose tolerance in the absence of adenosine A1 receptor signaling,” Diabetes, vol. 60, no. 10, pp. 2578–2587, 2011. View at Google Scholar
  63. G. K. Yang, B. B. Fredholm, T. J. Kieffer, and Y. N. Kwok, “Improved blood glucose disposal and altered insulin secretion patterns in adenosine A1 receptor knockout mice,” American Journal of Physiology, vol. 303, no. 2, pp. 180–190, 2012. View at Google Scholar
  64. J. G. Lee, D. G. Kang, J. R. Yu et al., “Changes in adenosine deaminase activity in patients with type 2 diabetes mellitus and effect of DPP-4 inhibitor treatment on ADA activity,” Diabetes and Metabolism Journal, vol. 35, no. 2, pp. 149–158, 2011. View at Google Scholar